Current IRB Studies*
IRB 2625 -- PI: Dr. Solomon with co-investigators Dr. Jon Wall and Stephen Kennel
Biodistribution study of 124I-11-1F4 mAb in patients with AL amyloid and Aβ Amyloid
This is a phase I biodistribution study of a potentially therapeutic amyloid-reactive monoclonal antibody designated 11-1F4 in patients with systemic peripheral light chain (AL) amyloidosis and cerebral (Aβ) amyloidosis (Alzheimer’s disease; AD). To date 25 AL patients and 3 AD patients have been imaged under the current e-IND. Patients are infused with either 2 or 5 mCi of 124I-labeled antibody and return on day 2 and 5 post injection for imaging on the mCT. Whole body images are acquired for each patient with additional PET data acquired from the brain or heart (list mode for cardiac-gating), as appropriate. Prompt gamma correction is implemented to correct for high energy gamma photons which caused photopenic artifacts in female patients that were imaged without this correction. The first report of the AL study will appear in Blood with mCT images of the 124I-11-1F4 mAb appearing on the cover of the journal.
*This is a partial list of IRB studies currently available. For more information please contact Dr. Amy LeBlanc.
The University of Tennessee Graduate School of Medicine
Molecular Imaging and Translational Research Program
UT Graduate School of Medicine
1924 Alcoa Hwy., Box 93
Knoxville, TN 37920-6999